Satoreotide trizoxetan

DRUG3 trials

Sponsors

Ipsen

Conditions

Breast CancerGastroenteropancreatic Neuroendocrine TumorsSmall Cell Lung Cancer and Breast Cancer

Phase 1

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

CompletedNCT02162446

IpsenGastroenteropancreatic Neuroendocrine Tumors

Start: 2014-06-30End: 2015-06-30Updated: 2019-10-02

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

TerminatedNCT03773133

IpsenSmall Cell Lung Cancer and Breast Cancer

Start: 2019-05-14End: 2019-10-10Updated: 2022-09-13

Phase 2

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

TerminatedNCT03697551

IpsenBreast Cancer

Start: 2018-10-22End: 2019-02-06Updated: 2020-09-07